News
Archives
- 2020
- Oct (1)
- Jul (1)
- Apr (1)
- 2019
- Dec (1)
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2018
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2017
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2016
- Oct (1)
- Apr (2)
- Jan (1)
- 2015
- 2014
- 2013
- Oct (1)
- Jul (1)
-
Apr (5)
- First investigator meeting for our new North Asia sites for the first time
- The National Cancer Institute (U.S) has recently labelled Aspirin in Colorectal Cancer as one of the most provocative questions in cancer
- We congratulate Dr Tham and team, and team from Sixth Affiliated Hospital
- Zhejiang and Zhongshan hospitals obtained IRB approval
- PIK3CA subgroup analysis included as a new secondary endpoint
- Jan (2)
- 2012
- Oct (2)
- Apr (1)
- Jan (1)
- 2011
- Oct (1)
- Jul (1)
- Apr (1)
Recent CAPP2 study shows that 2 yrs of daily Aspirin reduces incidence of primary colorectal cancers by 60% in patients with Lynch syndrome
Recently, the randomised CAPP2 study has updated their results (Burns J et al, Lancet 2011) and has shown that 2 yrs of daily Aspirin reduces incidence of primary colorectal cancers by 60% in patients with Lynch syndrome. Originally reported in the NEJM in 2008 as a negative trial – it has now turned positive on longer follow-up. This trial (together with the updated WHI study involving >100,000 women showing an 18-25% mortality benefit) has turned the spotlight on whether Aspirin should be recommended as primary prevention agent (accompanying editorial Anthony Chan et al, Lancet 2011).
Our study however seeks to answer a different question – relating to micrometastasis – and is as relevant as ever. It is to date, still the only secondary prevention study for colorectal cancer